敏感交叉配型联合HLA表位匹配预测活体肾移植结局
本研究回顾性分析330例补体依赖细胞毒性交叉配型阴性的活体肾移植患者,评估敏感免疫学检测(CDC-PRA、流式交叉配型、DSA及其C3d结合能力)与供受者HLA表位匹配对临床结局的影响,中位随访67个月。结果显示DSA-C3d阳性或高MFI-DSA独立预测急性排斥,HLA II类表位错配多者排斥风险高,既往排斥和FC-XM+/DSA+独立预测移植物丢失。
要点
- DSA-C3d阳性或高MFI-DSA独立预测急性排斥。
- HLA II类表位错配多者急性排斥风险更高。
- 既往排斥和FC-XM+/DSA+独立预测移植物丢失。
核心结论
- 联合流式交叉配型和固相检测与供受者HLA表位错配评估,是活体肾移植前免疫风险分层最准确的工具。
研究设计与样本
- 回顾性队列研究,纳入330例连续活体肾移植患者,均为补体依赖细胞毒性交叉配型阴性,平均随访67个月(范围24-190个月)。
主要发现
- 330例中35例(11%)CDC-PRA>20%,17例(5%)FC-XM+,30例(9%)DSA+,18例(5%)DSA-C3d+,仅10例所有供者特异性检测均阳性。
- DSA-C3d+者平均荧光强度(MFI)更高,cut-off MFI 6192准确预测补体结合(AUC=0.85,P=0.008)。
- DSA-C3d+(OR=6.64,P=0.038)或高MFI-DSA(OR=7.54,P=0.038)独立预测急性排斥。
- HLA II类表位错配差者急性排斥风险更高,尤其基线检测阴性者(OR=1.14,P=0.019)。
- 既往急性排斥和FC-XM+/DSA+(无论C3d状态)独立预测移植物丢失。
关键数值与推荐
- CDC-PRA>20%占11%,FC-XM+占5%,DSA+占9%,DSA-C3d+占5%。
- 预测补体结合的DSA MFI cut-off为6192(AUC=0.85,P=0.008)。
- DSA-C3d+预测急性排斥OR=6.64(P=0.038),高MFI-DSA预测急性排斥OR=7.54(P=0.038)。
- HLA II类表位错配差预测急性排斥OR=1.14(P=0.019)。
临床怎么用
- 活体肾移植前应联合流式交叉配型、固相DSA检测(含C3d)及供受者HLA表位错配评估进行免疫风险分层。
局限性
- 回顾性单中心队列研究,样本量330例,随访时间范围较宽(24-190个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite the different assays available for immune-risk stratification before living-donor kidney transplantation (LDKT), the precise type and number of tests to perform remain uncertain. METHODS: In a cohort of 330 consecutive LDKT patients, all of which were complement-dependent cytotoxicity (CDC)-crossmatch negative, we retrospectively analyzed the impact on main clinical outcomes of most sensitive immunoassays (complement-dependent cytotoxicity-panel-reactive antibody [CDC-PRA], flow cytometry crossmatch [FC-XM], donor-specific antibodies [DSAs], and their complement-binding capacity DSA-C3d]), together with donor/recipient HLA eplet matching. Mean follow-up was 67 months (range 24-190 months). RESULTS: Of 330 patients, 35 (11%) showed a CDC-PRA >20%; 17 (5%) FC-XM+; 30 (9%) DSA+, 18(5%) DSA-C3d+, with low overlapping results (10 patients positive in all donor-specific tests). Unlike HLA allele compatibility, the mean number of HLA class II eplet mismatches was higher in LDKT patients with positive baseline test results. DSA-C3d+ showed higher mean fluorescence intensity (MFI) DSA, with a cut-off MFI of 6192 accurately predicting complement fixation (area under the curve = 0.85, P = 0.008). Although all assays were associated with acute rejection (AR), only DSA-C3d+ (odds ratio [OR] = 6.64, P = 0.038) or high MFI-DSA (OR = 7.54, P = 0.038) independently predicted AR. Likewise, poorly HLA class II eplet-matched patients were at higher risk for AR, particularly patients with negative baseline test results (OR = 1.14, P = 0.019). Finally, previous AR and FC-XM+/DSA+, regardless of C3d positivity, independently predicted graft loss. CONCLUSION: Combining FC-XM and solid-phase assays with the evaluation of donor/recipient HLA eplet mismatches, are most accurate tools for immune-risk stratification prior LDKT.
引用
- Meneghini M, Melilli E, Martorell J, et al. Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome. Kidney Int Rep. 2018. PMID: 29989033. doi:10.1016/j.ekir.2018.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。